Результаты поиска - Birgit Bossenmaier

  • Отображение 1 - 14 результаты of 14
Отмена результатов
  1. 1
    Acquired Resistance to Antibody-Drug Conjugates

    Acquired Resistance to Antibody-Drug Conjugates по Denis M. Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen, Gerhard Niederfellner

    Опубликовано 2019
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  2. 2
    Protein kinase C isoforms β 1 and β 2 inhibit the tyrosine kinase activity of the insulin receptor

    Protein kinase C isoforms β 1 and β 2 inhibit the tyrosine kinase activity of the insulin receptor по Birgit Bossenmaier, Luitgard Mosthaf, Harald Mischak, A. Ullrich, Hans‐Ulrich Häring

    Опубликовано 1997
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

    Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models по Werner Scheuer, Thomas Friess, Helmut Burtscher, Birgit Bossenmaier, Josef Endl, Max Hasmann

    Опубликовано 2009
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  4. 4
    Differential activities of protein tyrosine phosphatases in intact cells.

    Differential activities of protein tyrosine phosphatases in intact cells. по Reiner Lammers, Birgit Bossenmaier, D E Cool, N. K. Tonks, Joseph Schlessinger, E H Fischer, A. Ullrich

    Опубликовано 1993
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling.

    Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. по G Kroder, Birgit Bossenmaier, Monika Kellerer, Edison Capp, B Stoyanov, A Mühlhöfer, Lucia Berti, Hiroyoshi Horikoshi, A. Ullrich, Hans-Ulrich Häring

    Опубликовано 1996
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

    Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer по Denis M. Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann, John Crown, Andrés Cervantes, Maja Weisser, Birgit Bossenmaier

    Опубликовано 2017
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity

    Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity по Yasmin Leshem, James O'Brien, Xiufen Liu, Tapan K. Bera, Masaki Terabe, Jay A. Berzofsky, Birgit Bossenmaier, Gerhard Niederfellner, Chin‐Hsien Tai, Yoram Reiter, Ira Pastan

    Опубликовано 2017
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation

    RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation по Christian Mirschberger, Christian Schiller, Michael Schräml, Nikolaos Dimoudis, Thomas Friess, Christian A. Gerdes, Ulrike Reiff, Valeria Lifke, Gabriele Hoelzlwimmer, Irene Kolm, Karl‐Peter Hopfner, Gerhard Niederfellner, Birgit Bossenmaier

    Опубликовано 2013
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <i>In Vivo</i> Efficacy Compared with Cetuximab

    GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <i>In Vivo</i> Efficacy Compared with Cetuximab по Christian A. Gerdes, Valeria Nicolini, Sylvia Herter, Erwin van Puijenbroek, Sabine M. Lang, Michaela Roemmele, Ekkehard Moessner, Olivier Freytag, Thomas Friess, Carola H. Ries, Birgit Bossenmaier, Hans Joachim Mueller, Pablo Umaña

    Опубликовано 2012
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody<sup>89</sup>Zr-RG7116

    ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody<sup>89</sup>Zr-RG7116 по Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub–de Hooge, K. Abiraj, Carolien P. Schröder, Linda Pot, Birgit Bossenmaier, Marlène Thomas, Gabriele Hölzlwimmer, Thomas Friess, Jos G.W. Kosterink, Elisabeth G.E. de Vries

    Опубликовано 2014
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Characterization of a re‐engineered, mesothelin‐targeted<i>Pseudomonas</i>exotoxin fusion protein for lung cancer therapy

    Characterization of a re‐engineered, mesothelin‐targeted<i>Pseudomonas</i>exotoxin fusion protein for lung cancer therapy по Frieder Bauss, Martin Lechmann, Ben‐Fillippo Krippendorff, Roland F. Staack, Frank Herting, Matthias Festag, Sabine Imhof-Jung, Friederike Hesse, Marc Pompiati, Gwendlyn Kollmorgen, Rita da Silva Mateus Seidl, Birgit Bossenmaier, Wilma Lau, Christian Schantz, Jan Olaf Stracke, Ulrich Brinkmann, Masanori Onda, Ira Pastan, Klaus Bosslet, Gerhard Niederfellner

    Опубликовано 2016
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

    The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner по Janet K. Peper-Gabriel, Marina Pavlidou, Lucia Pattarini, Aizea Morales‐Kastresana, Thomas J. Jaquin, Catherine Gallou, Eva-Maria Hansbauer, Marleen Richter, Hélène Lelièvre, Alix Scholer‐Dahirel, Birgit Bossenmaier, Celine Sancerne, Matthieu Rivière, Maximilien Grandclaudon, Markus Zettl, Rachida S. Bel Aiba, Christine Rothe, Véronique Blanc, Shane A. Olwill

    Опубликовано 2022
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors по Didier Meulendijks, Wolfgang Jacob, Maria Martinez‐García, Álvaro Taus, Martijn P. Lolkema, Emile E. Voest, Marlies H.G. Langenberg, Tania Fleitas, Andrés Cervantes, Maja J. De Jonge, Stefan Sleijfer, Morten Mau‐Sørensen, Marlène Thomas, Maurizio Ceppi, Georgina Meneses‐Lorente, Ian James, Céline Adessi, Francesca Michielin, K. Abiraj, Birgit Bossenmaier, Jan H.M. Schellens, Maja Weisser, Ulrik Lassen

    Опубликовано 2015
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  14. 14
    Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

    Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer по Denis M. Collins, Stephen F. Madden, Nicola Gaynor, Dalal AlSultan, Marion Le Gal, Alex J. Eustace, Kathy Gately, Clare Hughes, Anthony M. Davies, Thamir Mahgoub, Jo Ballot, Sinéad Toomey, Darran P. O’Connor, William M. Gallagher, Frankie A. Holmes, Virginia Espina, Lance A. Liotta, Bryan T. Hennessy, Kenneth J. O’Byrne, Max Hasmann, Birgit Bossenmaier, Norma O’Donovan, John Crown

    Опубликовано 2020
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: